大葉大學圖書館 |

Clinical pharmacokinetic and pharmacodynamic drug interactions associated with antimalarials[electronic resource] /

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
杜威分類號:	616.9362061
書名/作者:	Clinical pharmacokinetic and pharmacodynamic drug interactions associated with antimalarials/ by Tony K.L. Kiang, Kyle John Wilby, Mary H.H. Ensom.
作者:	Kiang, Tony K.L.
其他作者:	Wilby, Kyle John.
出版者:	Cham : : Springer International Publishing :, 2015.
面頁冊數:	vii, 146 p. : : ill., digital ;; 24 cm.
Contained By:	Springer eBooks
標題:	Antimalarials - Pharmacokinetics.
標題:	Antimalarials - Receptors
標題:	Medicine & Public Health.
標題:	Tropical Medicine.
標題:	Health Promotion and Disease Prevention.
標題:	Drug Safety and Pharmacovigilance.
ISBN:	9783319105277 (electronic bk.)
ISBN:	9783319105260 (paper)
內容註:	Introduction -- Pharmacology of Recommended Antimalarial Agents -- Drug Interaction Potential of Antimalarial Drugs Based on Known Metabolic Properties of Antimalarials -- Pharmacokinetic Drug Interactions Affecting Antimalarials -- Effects of Antimalarials on the Pharmacokinetics of Co-Administered Drugs -- Effects of Antimalarials on the Pharmacokinetics of Co-Administered Antimalarials -- Pharmacodynamic Interactions: Clinical Evidence for Combination Therapy, In Vitro Interactions, and In Vivo Interactions -- Limitations, Future Directions, and Conclusions.
摘要、提要註:	This comprehensive review provides a systematic, unbiased analysis, critique and summary of the available literature and generates novel clinical decision-making algorithms which can aid clinicians and scientists in practice management and research development. Potential mechanisms for the identified drug interactions are deduced from available preclinical and in vitro data which are interpreted in the context of the in vivo findings. Current limitations and gaps in the literature are summarized, and potential future research directions / experimentations are also suggested. In addition to the main objective to review the available clinical pharmacokinetic and pharmacodynamic drug interactions associated with WHO-recommended antimalarial drugs on the market today (i.e. chloroquine, amodiaquine, sulfadoxine, pyrimethamine, mefloquine, artemisinin, artemether, artesunate, dihydroartemisinin, artemotil, lumefantrine, primaquine, atovaquone, proguanil, piperaquine and quinine), this book also provides succinct chapter summaries on the epidemiology of malaria infection, diagnosis and therapeutics, in vivo pharmacology and chemistry, preclinical pharmacology, in vitro pharmacodynamics, in vitro reaction phenotyping, and in vitro drug-drug interaction data associated with the identified antimalarial drugs.
電子資源:	http://dx.doi.org/10.1007/978-3-319-10527-7

Clinical pharmacokinetic and pharmacodynamic drug interactions associated with antimalarials[electronic resource] /
Kiang, Tony K.L.

Clinical pharmacokinetic and pharmacodynamic drug interactions associated with antimalarials[electronic resource] /by Tony K.L. Kiang, Kyle John Wilby, Mary H.H. Ensom. - Cham :Springer International Publishing :2015. - vii, 146 p. :ill., digital ;24 cm.

Introduction -- Pharmacology of Recommended Antimalarial Agents -- Drug Interaction Potential of Antimalarial Drugs Based on Known Metabolic Properties of Antimalarials -- Pharmacokinetic Drug Interactions Affecting Antimalarials -- Effects of Antimalarials on the Pharmacokinetics of Co-Administered Drugs -- Effects of Antimalarials on the Pharmacokinetics of Co-Administered Antimalarials -- Pharmacodynamic Interactions: Clinical Evidence for Combination Therapy, In Vitro Interactions, and In Vivo Interactions -- Limitations, Future Directions, and Conclusions.

This comprehensive review provides a systematic, unbiased analysis, critique and summary of the available literature and generates novel clinical decision-making algorithms which can aid clinicians and scientists in practice management and research development. Potential mechanisms for the identified drug interactions are deduced from available preclinical and in vitro data which are interpreted in the context of the in vivo findings. Current limitations and gaps in the literature are summarized, and potential future research directions / experimentations are also suggested. In addition to the main objective to review the available clinical pharmacokinetic and pharmacodynamic drug interactions associated with WHO-recommended antimalarial drugs on the market today (i.e. chloroquine, amodiaquine, sulfadoxine, pyrimethamine, mefloquine, artemisinin, artemether, artesunate, dihydroartemisinin, artemotil, lumefantrine, primaquine, atovaquone, proguanil, piperaquine and quinine), this book also provides succinct chapter summaries on the epidemiology of malaria infection, diagnosis and therapeutics, in vivo pharmacology and chemistry, preclinical pharmacology, in vitro pharmacodynamics, in vitro reaction phenotyping, and in vitro drug-drug interaction data associated with the identified antimalarial drugs.

ISBN: 9783319105277 (electronic bk.)

Standard No.: 10.1007/978-3-319-10527-7doiSubjects--Topical Terms:

604909
Antimalarials
--Pharmacokinetics.

LC Class. No.: RC159.A5

Dewey Class. No.: 616.9362061

Clinical pharmacokinetic and pharmacodynamic drug interactions associated with antimalarials[electronic resource] /
LDR:02881nam a2200313 a 4500 001 425694
003 DE-He213
005 20150724100116.0
006 m d
007 cr nn 008maaau
008 151119s2015 gw s 0 eng d
020 $a 9783319105277 (electronic bk.)
020 $a 9783319105260 (paper)
024 7 $a 10.1007/978-3-319-10527-7 $2 doi
035 $a 978-3-319-10527-7
040 $a GP $c GP
041 0 $a eng
050 4 $a RC159.A5
072 7 $a MMRT $2 bicssc
072 7 $a MED097000 $2 bisacsh
082 0 4 $a 616.9362061 $2 23
090 $a RC159.A5 $b K46 2015
100 1 $a Kiang, Tony K.L. $3 604906
245 1 0 $a Clinical pharmacokinetic and pharmacodynamic drug interactions associated with antimalarials $h [electronic resource] / $c by Tony K.L. Kiang, Kyle John Wilby, Mary H.H. Ensom.
260 $a Cham : $b Springer International Publishing : $b Imprint: Adis, $c 2015.
300 $a vii, 146 p. : $b ill., digital ; $c 24 cm.
505 0 $a Introduction -- Pharmacology of Recommended Antimalarial Agents -- Drug Interaction Potential of Antimalarial Drugs Based on Known Metabolic Properties of Antimalarials -- Pharmacokinetic Drug Interactions Affecting Antimalarials -- Effects of Antimalarials on the Pharmacokinetics of Co-Administered Drugs -- Effects of Antimalarials on the Pharmacokinetics of Co-Administered Antimalarials -- Pharmacodynamic Interactions: Clinical Evidence for Combination Therapy, In Vitro Interactions, and In Vivo Interactions -- Limitations, Future Directions, and Conclusions.
520 $a This comprehensive review provides a systematic, unbiased analysis, critique and summary of the available literature and generates novel clinical decision-making algorithms which can aid clinicians and scientists in practice management and research development. Potential mechanisms for the identified drug interactions are deduced from available preclinical and in vitro data which are interpreted in the context of the in vivo findings. Current limitations and gaps in the literature are summarized, and potential future research directions / experimentations are also suggested. In addition to the main objective to review the available clinical pharmacokinetic and pharmacodynamic drug interactions associated with WHO-recommended antimalarial drugs on the market today (i.e. chloroquine, amodiaquine, sulfadoxine, pyrimethamine, mefloquine, artemisinin, artemether, artesunate, dihydroartemisinin, artemotil, lumefantrine, primaquine, atovaquone, proguanil, piperaquine and quinine), this book also provides succinct chapter summaries on the epidemiology of malaria infection, diagnosis and therapeutics, in vivo pharmacology and chemistry, preclinical pharmacology, in vitro pharmacodynamics, in vitro reaction phenotyping, and in vitro drug-drug interaction data associated with the identified antimalarial drugs.
650 0 $a Antimalarials $x Pharmacokinetics. $3 604909
650 0 $a Antimalarials $x Receptors $x Effect of drugs on. $3 604910
650 1 4 $a Medicine & Public Health. $3 463493
650 2 4 $a Tropical Medicine. $3 430941
650 2 4 $a Health Promotion and Disease Prevention. $3 463648
650 2 4 $a Drug Safety and Pharmacovigilance. $3 604911
700 1 $a Wilby, Kyle John. $3 604907
700 1 $a Ensom, Mary H.H. $3 604908
710 2 $a SpringerLink (Online service) $3 463450
773 0 $t Springer eBooks
856 4 0 $u http://dx.doi.org/10.1007/978-3-319-10527-7
950 $a Medicine (Springer-11650)